Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC

FRIDAY, Feb. 23, 2024 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant tislelizumab (TIS) plus chemotherapy with adjuvant TIS yields significant benefit in terms of event-free survival (EFS), according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news